Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

A community meeting organized by Easton council members to allow residents to hear more about a massive warehouse project ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a hit in recent years and the company has been looking to bridge the revenue ...

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...